Diabetes Ups Risk of HCC, Death in Patients With Hepatitis C

Share this content:
Diabetes Ups Risk of HCC, Death in Patients With Hepatitis C
Diabetes Ups Risk of HCC, Death in Patients With Hepatitis C

MONDAY, Dec. 19, 2016 (HealthDay News) -- For hepatitis C virus (HCV)-infected patients, diabetes mellitus (DM) is associated with increased risk of hepatocellular carcinoma (HCC) development and all-cause mortality, according to a study published online Dec. 8 in the Journal of Gastroenterology and Hepatology.

Ting-Shuo Huang, M.D., from the Chang Gung Memorial Hospital in Keelung, Taiwan, and colleagues used data from the Taiwanese National Health Insurance Research Database to evaluate the effect of DM on the development of HCC and on the transition from HCC to death. Newly diagnosed DM patients with HCV were enrolled and were propensity-score matched with HCV patients without DM (1,686 patients in each cohort).

The researchers found that, compared with the non-DM cohort, the DM cohort had higher cumulative hazards for "start-to-HCC," "start-to-death," and "HCC-to-death" transitions. After 10 years of follow-up, the cumulative probability of death with or without HCC was higher in the DM versus non-DM cohort. DM correlated with significantly increased risk for transition from "start-to-HCC," "start-to-death," and "HCC-to-death" (adjusted hazard ratios, 1.36, 2.61, and 1.36, respectively). Over time there was a decrease in the effect of liver cirrhosis on "start-to-HCC" and "start-to-death" transitions, especially within two years.

"DM increased the risk of HCC development in HCV-infected patients and the risk of all-cause mortality in patients with or without HCC," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »